Vaxart
Clinical-stage biotechnology company developing oral recombinant tablet vaccines using a modular vector–adjuvant–antigen platform to induce mucosal and systemic immunity. Public materials describe preclinical animal studies, multiple human clinical trials (Phase 1–2b and challenge studies), analytical and process development, thermostable oral tablet formulation, manufacturing support functions, and regulatory and pharmacovigilance activities. Development programs include pill vaccine candidates targeting coronavirus, norovirus, and influenza, and a therapeutic vaccine program for human papillomavirus (HPV). The company has peer-reviewed publications and government collaborations for large clinical programs.
Industries
Nr. of Employees
medium (51-250)
Patents
Method for the synthesis of a hydrazine that can be used in the treatment of the papilloma virus
US-9908858-B2
View DetailsAnhydrous crystalline free base form of 6-{2-[1 -(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-3-ethoxy-1,2-benzisoxazole
US-9802926-B2
View Details
Method for the synthesis of a hydrazine that can be used in the treatment of the papilloma virus
US-9908858-B2
View DetailsAnhydrous crystalline free base form of 6-{2-[1 -(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-3-ethoxy-1,2-benzisoxazole
US-9802926-B2
View DetailsProducts
Oral recombinant tablet vaccine candidates
Gene-based oral tablet vaccine candidates that express target antigens via a viral vector platform to elicit mucosal and systemic immunity; pipeline includes candidates for coronavirus, norovirus and influenza, and a therapeutic program for HPV.
Oral recombinant tablet vaccine candidates
Gene-based oral tablet vaccine candidates that express target antigens via a viral vector platform to elicit mucosal and systemic immunity; pipeline includes candidates for coronavirus, norovirus and influenza, and a therapeutic program for HPV.
Services
Clinical development services for orally delivered recombinant tablet vaccine candidates including trial design, execution, immunogenicity and safety assessments, and clinical sample operations.
Analytical method development, automated bioassays, chromatographic separations, and product characterization to support development, release testing and stability programs.
Upstream/downstream process development, formulation development, lyophilization and MSAT support to produce clinical materials and prepare processes for scale-up.
Clinical development services for orally delivered recombinant tablet vaccine candidates including trial design, execution, immunogenicity and safety assessments, and clinical sample operations.
Analytical method development, automated bioassays, chromatographic separations, and product characterization to support development, release testing and stability programs.
Upstream/downstream process development, formulation development, lyophilization and MSAT support to produce clinical materials and prepare processes for scale-up.
Expertise Areas
- Oral vaccine development and solid oral dosage formulation
- Mucosal immunology and induction of mucosal/systemic responses
- Clinical trial management (Phase 1–2b, randomized and comparator-controlled)
- Preclinical efficacy and human challenge models
Key Technologies
- Oral tablet vaccine delivery
- Viral vector–based vaccines (non-replicating)
- Modular antigen–adjuvant platform
- Molecular adjuvants (TLR agonists)
News & Updates
Company presentation at an investor conference.
Announcement of expansion of intellectual property portfolio with a European patent covering norovirus vaccine technology.
Report of 12-month safety data from a 400-participant sentinel cohort of a Phase 2b clinical trial of an oral tablet COVID-19 vaccine candidate.
Multiple peer-reviewed journal articles reporting preclinical efficacy, demonstration of mucosal and systemic immunogenicity in humans, and results from Phase 1 and Phase 2 clinical and challenge studies for orally delivered viral-vectored vaccines.
Company presentation at an investor conference.
Announcement of expansion of intellectual property portfolio with a European patent covering norovirus vaccine technology.
Report of 12-month safety data from a 400-participant sentinel cohort of a Phase 2b clinical trial of an oral tablet COVID-19 vaccine candidate.
Multiple peer-reviewed journal articles reporting preclinical efficacy, demonstration of mucosal and systemic immunogenicity in humans, and results from Phase 1 and Phase 2 clinical and challenge studies for orally delivered viral-vectored vaccines.